Mineralys Therapeutics (MLYS) Change in Acquisitions & Divestments (2022 - 2026)

Mineralys Therapeutics has disclosed Change in Acquisitions & Divestments across 5 years of filings, most recently posting $302.5 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $302.5 million, up 764.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $692.5 million (up 51.86% YoY), and the FY2025 annual result was $425.0 million, down 13.0% from the prior year.
• Change in Acquisitions & Divestments came in at $302.5 million for Q1 2026 at Mineralys Therapeutics, up from $165.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $302.5 million in Q1 2026 to a low of $22.5 million in Q1 2023.
• The 5-year median for Change in Acquisitions & Divestments is $71.2 million (2024), against an average of $103.8 million.
• Across the five-year window, Change in Acquisitions & Divestments plunged 48.15% in 2025 and soared 764.29% in 2026, its largest moves.
• Mineralys Therapeutics' Change in Acquisitions & Divestments stood at $50.0 million in 2022, then climbed by 30.0% to $65.0 million in 2023, then surged by 126.92% to $147.5 million in 2024, then climbed by 11.86% to $165.0 million in 2025, then soared by 83.33% to $302.5 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $302.5 million (Q1 2026), $165.0 million (Q4 2025), and $150.0 million (Q3 2025), per Business Quant data.